Ovid Therapeutics Inc. (OVID)


-0.10 (-2.47%)
Symbol OVID
Price $3.745
Beta 1.143
Volume Avg. 0.11M
Market Cap 264.102M
Shares () -
52 Week Range 1.405-3.89
1y Target Est -
DCF Unlevered OVID DCF ->
DCF Levered OVID LDCF ->
ROE -36.63% Strong Sell
ROA -34.89% Strong Sell
Operating Margin -
Debt / Equity 17.38% Neutral
P/E -4.93 Strong Sell
P/B 1.99 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest OVID news

Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir
NASDAQ Global Select

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.